Skip to main content
TipRanks
Go Ultimate75% OFF

Urogen Pharma (UR8) AI Stock Analysis

1 Followers
DE:UR8

Urogen Pharma

(Frankfurt:UR8)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Zosturi commercial growth and adoptionRapid Zosturi revenue growth, increasing repeat use, and expanding physician adoption indicate improving commercial traction for the company’s lead growth product. Continued penetration across community practices could support durable revenue expansion as more prescribers gain experience with the treatment.
Negative Factors
Persistent cash burnSubstantial ongoing cash outflows mean UroGen has not yet converted commercial revenue into internally generated funding. Continued investment in launches and clinical programs may require external capital if the anticipated profitability improvement is delayed, limiting financial flexibility over the medium term.

Urogen Pharma (UR8) vs. iShares MSCI Germany ETF (EWG)

-50%-25%0%25%50%75%100%125%DE:UR8+16.92%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 1.28B
Dividend Yield
―
Average Volume (3M)
203
Price to Earnings (P/E)
-19.8
Beta (1Y)
-0.49
Revenue Growth
147.54%
EPS Growth
63.72%
Country
Germany
Employees
300
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Urogen Pharma Business Overview & Revenue Model

Company Description

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technolog...

Urogen Pharma Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:-24.27%|Next Earnings Date:Mar 18, 2027
Earnings Call SentimentPositive

The call was strongly constructive, led by 35% sequential Zosturi revenue growth, expanding prescriber and repeat-use metrics, major UGN-103 regulatory progress, pipeline advancement, improved financial results, and management's expectation of profitability and positive cash flow in the fourth quarter. The principal challenges were Jelmyto revenue pressure from a one-time adjustment and clinical-trial competition, elevated operating expenses, adoption barriers, and near-term seasonality. Highlights significantly outweighed lowlights.

Positive Updates

Strong Zosturi Revenue Growth
Zosturi generated $68 million in net product revenue in the third quarter, representing 35% sequential quarter-over-quarter growth. Management said increasing repeat utilization, broader physician adoption, and continued expansion into community practices are strengthening the commercial trends.

Negative Updates

Jelmyto Revenue Decline and Gross-to-Net Adjustment
Jelmyto net product revenue was $21 million in the third quarter, compared with $22 million in the second quarter. The quarter included a one-time unfavorable gross-to-net adjustment of approximately $1.5 million related to the CMS discarded drug provision true-up.

Company Guidance

For 2026, UroGen updated Jelmyto net product revenue guidance to approximately $90 million, is not issuing full-year Zosturi guidance, and is maintaining full year operating expense guidance of $260 million to $270 million including $20 million to $24 million of noncash share based compensation, with operating expenses expected to land toward the upper end of the guidance range; the company expects quarter over quarter revenue growth for Zosturi in the fourth quarter of 26, is comfortable with where consensus sits for the full year for Zosturi, and anticipates achieving profitability and generating positive cash flow in the fourth quarter of 26. For 2027, the company is not issuing guides for Zosturi, although it said growing $15 to $20 million this year is a reasonable framework, and described Jelmyto as likely to be within that 100 to 150 range long term.

Urogen Pharma Risk Analysis

Urogen Pharma disclosed 81 risk factors in its most recent earnings report. Urogen Pharma reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Urogen Pharma Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:UR8 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
PBYIPBYI64Neutral$401.70M16.3217.52%―9.35%-37.15%
VSTMVSTM54Neutral$1.03B-4.42-359.49%―649.65%54.01%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
NUVBNUVB49Neutral$1.41B-10.11-49.11%―654.19%39.07%
ZLABZLAB49Neutral$3.24B-14.26-31.11%―0.25%8.33%
KURAKURA48Neutral$713.90M-2.35-336.24%―-23.76%-33.09%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%DE:UR8VSTMPBYIKURAZLABNUVBDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:UR8 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:UR8Urogen Pharma23.153.1515.75%
VSTMVerastem Inc8.18-0.97-10.60%
PBYIPuma Biotechnology7.772.8156.65%
KURAKura Oncology7.77-3.08-28.39%
ZLABZai Lab Ltd24.603.6817.59%
NUVBNuvation Bio Inc3.99-0.68-14.56%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.